Fol­low­ing Vray­lar suc­cess, Ab­b­Vie ex­tends part­ner­ship with Gedeon Richter to neu­ropsy­chi­atric dis­eases

Ab­b­Vie is see­ing dol­lar signs as it looks to ex­pand the la­bel on Vray­lar, its Gedeon Richter-part­nered an­tipsy­chot­ic block­buster. And now, it wants to know what else the Hun­gar­i­an phar­ma com­pa­ny has up its sleeve.

Af­ter see­ing some pre­clin­i­cal re­sults from Richter, Ab­b­Vie has ex­tend­ed its col­lab­o­ra­tion with the com­pa­ny to in­clude new dopamine re­cep­tor mod­u­la­tors for neu­ropsy­chi­atric dis­eases. The deal, un­veiled Fri­day, will in­clude “sev­er­al new chem­i­cal en­ti­ties,” though the part­ners seem to be keep­ing the fi­nan­cial terms un­der wraps.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER